Bio Meat Foodtech - Limited Partnership
TTASE:BIMT27.90
ILA
-1.20
(-4.12%)
ISIN
IL0011739054
Return %
Stock
S&P 500
1Y
-30.77
14.20
3Y
-74.07
81.12
5Y
-65.12
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Gilles Michel Gamon
- Full Time Employees
- 4
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 1 Hatmarim Street, Southern Industrial Zone Petach Tikva HM Israel 7710301
- IPO Date
- Mar 14, 2021
- Website
- biomeat.co.il
- Similar Companies
- Business
- Bio Meat Foodtech - Limited Partnership (BIMT.TA) operates as a publicly traded Israeli investment firm focused on growth capital in the FoodTech sector; it invests in and supports R&D companies developing meat substitutes, alternative proteins, innovative food production methods, nutritional supplements, and animal- or plant-originated food innovations. Core activities encompass principal investments and holdings in early-stage FoodTech ventures addressing sustainability challenges like rising animal protein demand, environmental impacts of factory farming, and supply chain reliability; key strategic assets include a management team with food industry expertise and a partnership with Solbar Food Technologies, a leading Israeli plant protein producer. The firm provides funding, advisory services, and operational support to portfolio companies targeting transparent, ethical food solutions for consumer and industrial markets. Founded in 2020 and headquartered in Petah Tikva, Israel, Bio Meat Foodtech maintains a lean structure with two employees and leadership under CEO Jill Michelle Gamon and CFO Asher Zamir CPA. It operates primarily in Israel with a focus on global FoodTech opportunities, emphasizing R&D projects in cultivated meat, plant-based alternatives, and precision production technologies. The company trades on the Tel Aviv Stock Exchange, positioning it as an accessible vehicle for investors in high-growth alternative protein segments. Recent developments reflect ongoing portfolio management amid FoodTech sector consolidation, including exposure to trends like cultivated meat mergers (e.g., Orbillion Bio's 2025 acquisition by Fork & Good) and funding challenges; no major new investments, acquisitions, or partnerships by the firm itself announced in 2024-2025. Leadership updates feature board changes with Maya Hen joining as director in 2024. Financials show trailing twelve-month revenue of -ILS9.02 million and net income of -ILS7.88 million, underscoring investment-stage losses typical of R&D-focused funds.
Company News
Eshbal Announces Appointment of Nir Peles to Board of Directors, Achievement of Revenue Milestones and Ontario Continuance